2022 UMB Entrepreneur of the Year Awards Presentation Oct. 24th, 2022 On October 24, 2022 this year’s David J. Ramsay Entrepreneur of the Year Awards winner Allan Doctor, MD, gave a lecture demonstrating the impact his entrepreneurship and research have had on the...
UMB Honors KaloCyte Co-Founder Allan Doctor, MD as David J. Ramsay Entrepreneur of the Year Sept. 30th, 2022 The University of Maryland, Baltimore (UMB) has announced the recipients of their 2022 Founders Week awards in recognition of the extraordinary work of the...
New Book Released: “Blood Substitutes and Oxygen Biotherapeutics”; Henry Liu, Alan D. Kaye, and Jonathan S. Jahr; Editors Aug. 22nd, 2022 This new book features a full chapter co-authored by KaloCyte’s Research and Development team and serves as a comprehensive and...
State of the Art Report: Nanotechnology Applications for Combat Casualty Care – HDIAC Aug. 22nd, 2022 ErythroMer™ featured in the August 2022 State of the Art report issued by the Homeland Defense & Security Information Analysis Center (HDIAC) READ MORE...
KaloCyte Closes Investment from New York Blood Center July. 20th, 2022 KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMer™, announced it has closed an investment from New York Blood Center, Inc. (NYBC). READ MORE Search for:...
One of KaloCyte’s co-founders, Dr. Allan Doctor, was among several experts interviewed for and quoted in the article on synthetic blood research, and KaloCyte’s ErythroMer and developmental status is featured. Click here to read the article featured in The Washington...
